{
  "id": 3633,
  "language": "english",
  "hallucination": "yes",
  "ground_truth_source": "Original_text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Co-hosts",
      "inferred_vibe": "Informative and conversational"
    },
    "dialogue_turns": [
      {
        "speaker": "Host_A",
        "text": "Welcome back to the show! Today, we're, uh, diving into something pretty incredible about our own bodies, and a company that's really shaking up the biotech world.",
        "tts_text": "Welcome back to the show! Today, we're, uh, diving into something pretty incredible about our own bodies, and a company that's really shaking up the biotech world.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_B",
        "text": "Yeah, it's wild, right? Every time you get, like, infected by a bug or a virus, your immune system just kicks into high gear, making these tiny little treatments – antibodies – to fight it off.",
        "tts_text": "Yeah, it's wild, right? Every time you get, like, infected by a bug or a virus, your immune system just kicks into high gear, making these tiny little treatments - antibodies - to fight it off.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Every time youre infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Exactly! And these antibodies are, um, molecularly unique to each person. They either destroy the invaders or, like, mark them for other killer cells to track down. It's, uh, truly spectacular, as one guy put it.",
        "tts_text": "Exactly! And these antibodies are, um, molecularly unique to each person. They either destroy the invaders or, like, mark them for other killer cells to track down. It's, uh, truly spectacular, as one guy put it.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "That guy would be Carl Hansen, right? The 46-year-old CEO of AbCellera Biologics. He was apparently, like, geeking out describing this process over Zoom, saying, \"We can make 100 different antibodies!\"",
        "tts_text": "That guy would be Carl Hansen, right? The forty six-year-old C E O of AbCellera Biologics. He was apparently, like, geeking out describing this process over Zoom, saying, We can make one hundred different antibodies!",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "We can make 100 trillion different antibodies, he exclaims.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "He used to be a college professor, actually, until 2018. That's when he left to focus on AbCellera, which he co-founded with fellow researchers from the University of British Columbia. It makes sense, universities are great for, um, testing new ideas.",
        "tts_text": "He used to be a college professor, actually, until twenty eighteen. That's when he left to focus on AbCellera, which he co-founded with fellow researchers from the University of British Columbia. It makes sense, universities are great for, um, testing new ideas.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Hansen was oneuntil 2019, when he left to focus on Vancouver- based AbCellera Biologics, cofounded with fellow researchers from the University of British Columbia in 2012.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "What's really interesting is AbCellera's totally different approach from, like, traditional biotech companies. Most of them try to build out a whole drug company, but AbCellera just focuses on the *discovery* process.",
        "tts_text": "What's really interesting is AbCellera's totally different approach from, like, traditional biotech companies. Most of them try to build out a whole drug company, but AbCellera just focuses on the discovery process.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "AbCellera takes a vastly different approach. Instead of trying to build a vertically integrated drug company, it is focused solely on the discovery process.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Right, the earliest, most essential part. They call it \"drug discovery as a service.\" They're not trying to take a drug all the way to market themselves.",
        "tts_text": "Right, the earliest, most essential part. They call it drug discovery as a service. They're not trying to take a drug all the way to market themselves.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Instead it offers what might be described as drug discovery as a service.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "[interrupts] So they partner with, like, big pharma companies instead?",
        "tts_text": "So they partner with, like, big pharma companies instead?",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "It works with 90 outside businesses, including pharma giants Pfizer, Gilead and Novartis.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Precisely! They work with around 80 outside businesses, including giants like Pfizer and Novartis. These companies ask AbCellera to find specific antibodies, and then AbCellera uses its tech to find the best prospects.",
        "tts_text": "Precisely! They work with around eighty outside businesses, including giants like Pfizer and Novartis. These companies ask AbCellera to find specific antibodies, and then AbCellera uses its tech to find the best prospects.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "It works with 90 outside businesses, including pharma giants Pfizer, Gilead and Novartis.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "And their highest-profile success to date, I mean, that's got to be with Covid-19, right?",
        "tts_text": "And their highest-profile success to date, I mean, that's got to be with Covid-nineteen, right?",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "In its highest-profile success to date, AbCellera examined thousands of antibodies derived from the blood of people who had recovered from Covid-19 in order to identify the antibodies that did the best job fighting the virus.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Oh, absolutely. They examined thousands of antibodies from recovered Covid patients, identified the best ones, and then turned them over to Eli Lilly.",
        "tts_text": "Oh, absolutely. They examined thousands of antibodies from recovered Covid patients, identified the best ones, and then turned them over to Eli Lilly.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "It then turned over the most promising antibodies to drug company Eli Lilly.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "And that's how we got bamlanivimab, wasn't it? I remember hearing about that. How fast did that whole process go from partnership to trials?",
        "tts_text": "And that's how we got bamlanivimab, wasn't it? I remember hearing about that. How fast did that whole process go from partnership to trials?",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Clinical trials of one of those antibodies, bamlanivimab, began in Mayjust 90 days after the partnership started.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Incredibly fast. Clinical trials started in June, just 80 days after the partnership began. And then, uh, emergency-use authorization from the FDA in November.",
        "tts_text": "Incredibly fast. Clinical trials started in June, just eighty days after the partnership began. And then, uh, emergency-use authorization from the F D A in November.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Clinical trials of one of those antibodies, bamlanivimab, began in Mayjust 90 days after the partnership started.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "Wow. That must have meant, like, huge money for them. I mean, royalties from a drug like that...",
        "tts_text": "Wow. That must have meant, like, huge money for them. I mean, royalties from a drug like that...",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      },
      {
        "speaker": "Host_A",
        "text": "Yeah, huge. The federal government bought 900,000 doses for $1.1 billion. Eli Lilly expects up to $1.9 billion in revenue from Covid therapeutics in 2021, and AbCellera is set to earn an estimated $250 million in royalties on those sales.",
        "tts_text": "Yeah, huge. The federal government bought nine hundred thousand doses for one point one billion dollars. Eli Lilly expects up to one point nine billion dollars in revenue from Covid therapeutics in twenty twenty one, and AbCellera is set to earn an estimated two hundred fifty million dollars in royalties on those sales.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "The federal government has contracted to purchase 950,000 doses of the drug for $1.2 billion. Eli Lilly issued guidance in mid-December expecting up to $2 billion in revenue from Covid-19 therapeutics in 2021... AbCellera... will earn estimated royalties of $270 million on those sales, according to Credit Suisse.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "So, this speed, it's not just about getting treatments out faster, it's a huge financial game-changer too, uh, for the company?",
        "tts_text": "So, this speed, it's not just about getting treatments out faster, it's a huge financial game-changer too, uh, for the company?",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "From a financial perspective, every year that you save is a huge opportunity cost for investors, says Gal Munda, an analyst at Berenberg Capital Markets.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Absolutely. As one analyst put it, every year you save in development is a massive opportunity cost for investors. Faster to market means quicker revenue and, like, less development cost.",
        "tts_text": "Absolutely. As one analyst put it, every year you save in development is a massive opportunity cost for investors. Faster to market means quicker revenue and, like, less development cost.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The shorter time frame saves millions in development costs while enabling revenues to come in sooner than expected. From a financial perspective, every year that you save is a huge opportunity cost for investors, says Gal Munda, an analyst at Berenberg Capital Markets.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "And Hansen himself, he's, uh, a billionaire now, isn't he? Thanks to their hot IPO.",
        "tts_text": "And Hansen himself, he's, uh, a billionaire now, isn't he? Thanks to their hot I P O.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Hansen is now worth $3 billion, thanks to the companys white-hot December IPO.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "[interrupts] Oh yeah, $2.8 billion post-IPO. He's pretty low-key about it though, just saying it \"feels a little bit surreal.\"",
        "tts_text": "Oh yeah, two point eight billion dollars post-I P O. He's pretty low-key about it though, just saying it feels a little bit surreal.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Hansen is now worth $3 billion, thanks to the companys white-hot December IPO.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_B",
        "text": "But he sees this Covid example as, like, proof positive of their business model and technology.",
        "tts_text": "But he sees this Covid example as, like, proof positive of their business model and technology.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "If this example of Covid shows one thing, to me, its the proof point of the business model and the technology.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "Host_A",
        "text": "Exactly. It's a testament to how innovation can totally, um, disrupt an industry. Really fascinating stuff.",
        "tts_text": "Exactly. It's a testament to how innovation can totally, um, disrupt an industry. Really fascinating stuff.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": ""
      }
    ]
  }
}